Additive manufacturing (AM) methods are being used in the quickly developing field of pharmaceutical additive manufacturing, commonly referred to as three-dimensional (3D) printing in the pharmaceutical business to develop consumer-centric pharmaceutical products. The potential for additive manufacturing to completely transform drug development and manufacturing by offering advantages such as personalized medicine, complex formulation systems, and production on-demand. Recently the applicability of biomaterials in 3D printing have gained significant interest among the researcher due to biodegradability and safety on use. Lignin, which is derived from lignocellulose and is the most prevalent aromatic biomass among the studied materials, is widely acknowledged as a promising biomaterial to produce pharmaceuticals using AM technology. Plant cell walls contain lignin, which has a macromolecular structure made up of guaiacyl, syringyl, and p-hydroxyphenyl units joined by carbon-carbon and ether bonds. These properties give lignin its unique bioactivity, amphiphilicity, and designability, which make it an intriguing candidate for use in biomedicines, ecological and engineering utility. The composition and origin of lignin, as well as its purification and the current state of 3D printed pharmaceutical products, are briefly reviewed in this chapter, which also identifies the main challenges. Additionally, summary on 3D printing technology have been presented to further understand the rapid prototyping technologies.